Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health · Closes 20 Nov 2026

PAR-25-226

Know if you qualify before you write anything

We have this funder's eligibility rules and full description. Build a checklist and get every requirement as its own row, quoted from the notice, with the eligibility rules first so you can rule yourself in or out in a minute rather than a morning.

Build the checklist Read the full notice on Grants.gov

Free for published grants. No account needed.

Funding agency: National Institutes of Health
Closing date: 20 Nov 2026
Posted: 23 Nov 2024
CFDA: 93.242

Get new grants each morning

One email with every new opportunity matching you: title, agency, deadline, award range and the link to apply.

Subscribe for alerts

Source: Grants.gov. The international flag is read from the funder's own wording and is a filter, not legal advice. Always confirm eligibility against the official notice before applying.